Natalie Sacks
Overview
Explore the profile of Natalie Sacks including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
667
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Santegoets S, Stam A, Lougheed S, Gall H, Jooss K, Sacks N, et al.
J Immunother Cancer
. 2015 Jul;
2:31.
PMID: 26196012
Background: Cancer-related disturbances in myeloid lineage development, marked by high levels of myeloid-derived suppressor cells (MDSC) and impaired dendritic cell (DC) development, are associated with poor clinical outcome due to...
2.
Santegoets S, Stam A, Lougheed S, Gall H, Scholten P, Reijm M, et al.
Cancer Immunol Immunother
. 2012 Aug;
62(2):245-56.
PMID: 22878899
Immune checkpoint blockade enhances antitumor responses, but can also lead to severe immune-related adverse events (IRAE). To avoid unnecessary exposure to these potentially hazardous agents, it is important to identify...
3.
van den Eertwegh A, Versluis J, van den Berg H, Santegoets S, Jeroen A van Moorselaar R, van der Sluis T, et al.
Lancet Oncol
. 2012 Feb;
13(5):509-17.
PMID: 22326922
Background: The granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells vaccine (GVAX) has antitumour activity against prostate cancer; preclinical studies have shown potent synergy when combined with ipilimumab, an antibody that...
4.
Higano C, Corman J, Smith D, Centeno A, Steidle C, Gittleman M, et al.
Cancer
. 2008 Jul;
113(5):975-84.
PMID: 18646045
Background: This open-label, multicenter, dose-escalation study evaluated multiple dose levels of immunotherapy in patients with metastatic hormone-refractory prostate cancer (HRPC). The immunotherapy, based on the GVAX platform, consisted of 2...
5.
Small E, Sacks N, Nemunaitis J, Urba W, Dula E, Centeno A, et al.
Clin Cancer Res
. 2007 Jul;
13(13):3883-91.
PMID: 17606721
Purpose: This trial evaluated the safety, clinical activity, and immunogenicity of an allogeneic cellular immunotherapy in 55 chemotherapy-naïve patients with hormone-refractory prostate cancer (HRPC). The immunotherapy, based on the GVAX...
6.
Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A, et al.
J Immunother
. 2007 Jan;
30(1):1-15.
PMID: 17198079
Therapeutic cancer vaccines are a heterogeneous group of complex biologics with distinctly different clinical characteristics than cytotoxic agents. The current clinical development paradigm used for oncology drug development is based...
7.
Simons J, Sacks N
Urol Oncol
. 2006 Sep;
24(5):419-24.
PMID: 16962494
New approaches to therapeutics of advanced prostate cancer are urgently needed. GVAX (granulocyte-macrophage colony-stimulating factor [GM-CSF] gene transduced irradiated prostate cancer vaccine cells) offers the possibility that "host versus prostate...